18.91
price up icon2.77%   0.51
after-market アフターアワーズ: 18.87 -0.04 -0.21%
loading
前日終値:
$18.40
開ける:
$18.59
24時間の取引高:
707.75K
Relative Volume:
0.92
時価総額:
$1.38B
収益:
$9.98M
当期純損益:
$-154.08M
株価収益率:
-7.3295
EPS:
-2.58
ネットキャッシュフロー:
$-159.66M
1週間 パフォーマンス:
-9.22%
1か月 パフォーマンス:
+20.22%
6か月 パフォーマンス:
-28.56%
1年 パフォーマンス:
-55.20%
1日の値動き範囲:
Value
$17.85
$19.24
1週間の範囲:
Value
$17.85
$21.23
52週間の値動き範囲:
Value
$14.40
$47.00

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
名前
Celldex Therapeutics Inc
Name
セクター
Healthcare (1154)
Name
電話
908-200-7500
Name
住所
53 FRONTAGE ROAD, HAMPTON
Name
職員
186
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
CLDX's Discussions on Twitter

CLDX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CLDX
Celldex Therapeutics Inc
18.91 1.38B 9.98M -154.08M -159.66M -2.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.82 130.98B 11.10B -988.90M -978.00M -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 64.65B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
622.93 39.39B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.55 34.32B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
232.25 28.03B 3.81B -644.79M -669.77M -6.24

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-28 開始されました Canaccord Genuity Buy
2025-03-20 開始されました Morgan Stanley Overweight
2025-02-13 開始されました UBS Buy
2024-10-07 開始されました Citigroup Buy
2024-09-30 開始されました Goldman Neutral
2024-09-27 ダウングレード Wolfe Research Outperform → Peer Perform
2024-06-18 開始されました Stifel Buy
2024-06-11 開始されました Wolfe Research Outperform
2023-12-20 開始されました TD Cowen Outperform
2023-11-10 アップグレード Wells Fargo Underweight → Equal Weight
2023-08-22 開始されました Wells Fargo Underweight
2021-09-17 開始されました Jefferies Buy
2021-09-10 開始されました SVB Leerink Outperform
2021-07-22 開始されました Guggenheim Buy
2020-02-21 開始されました Cantor Fitzgerald Overweight
2017-08-01 再開されました H.C. Wainwright Buy
2016-11-07 開始されました Aegis Capital Buy
2016-03-08 ダウングレード Jefferies Buy → Hold
2016-03-07 ダウングレード Guggenheim Buy → Neutral
2016-03-07 ダウングレード Leerink Partners Outperform → Mkt Perform
2016-03-07 ダウングレード Wedbush Outperform → Neutral
2016-03-01 開始されました H.C. Wainwright Buy
2015-08-11 繰り返されました Brean Capital Buy
2015-08-11 繰り返されました Oppenheimer Outperform
2015-08-11 繰り返されました ROTH Capital Buy
2015-06-02 繰り返されました WBB Securities Strong Buy
2014-11-17 繰り返されました ROTH Capital Buy
2014-03-04 繰り返されました Oppenheimer Outperform
2013-07-08 繰り返されました Cantor Fitzgerald Buy
2013-03-08 繰り返されました Cantor Fitzgerald Buy
2013-02-26 繰り返されました Oppenheimer Outperform
2013-01-10 繰り返されました Cantor Fitzgerald Buy
2012-10-02 繰り返されました Oppenheimer Outperform
2012-09-14 繰り返されました Cantor Fitzgerald Buy
すべてを表示

Celldex Therapeutics Inc (CLDX) 最新ニュース

pulisher
May 07, 2025

Stock Market Recap: Celldex Therapeutics Inc (CLDX) Concludes at 18.40, a -9.31 Surge/Decline - DWinneX

May 07, 2025
pulisher
May 07, 2025

Cantor Fitzgerald maintains Celldex stock Overweight with $67 target By Investing.com - Investing.com Canada

May 07, 2025
pulisher
May 06, 2025

Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating fro - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Celldex Therapeutics (CLDX) Receives Reiterated 'Buy' Rating from HC Wainwright | CLDX Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

New Clinical Data Reveals Breakthrough Potential for Celldex's EoE Treatment at Major Medical Conference - Stock Titan

May 05, 2025
pulisher
May 02, 2025

Celldex: Q4 Earnings Snapshot - Barchart.com

May 02, 2025
pulisher
May 02, 2025

Market Insights: Celldex Therapeutics Inc (CLDX)’s Notable Drop of -0.58, Closing at 20.71 - DWinneX

May 02, 2025
pulisher
May 02, 2025

A look into Celldex Therapeutics Inc (CLDX)’s deeper side - Sete News

May 02, 2025
pulisher
May 02, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

May 02, 2025
pulisher
May 01, 2025

Celldex Therapeutics Inc’s results are impressive - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

The Attractiveness of Investing In Celldex Therapeutics Inc (CLDX) is Growing - knoxdaily.com

Apr 30, 2025
pulisher
Apr 29, 2025

Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Analyst Expectations For Celldex Therapeutics's Future - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Canaccord Genuity Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Canaccord Initiates Coverage on Celldex (CLDX) with a Positive O - GuruFocus

Apr 28, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

Celldex Therapeutics Inc [CLDX] Records 200-Day SMA of $28.24 - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Regeneron Pharmaceuticals, Inc [REGN] Shares Rise 0.40 % on Wednesday - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

How to interpret Celldex Therapeutics Inc (CLDX)’s stock chart patterns - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Chronic Spontaneous Urticaria Market Set for Robust Growth From - openPR.com

Apr 23, 2025
pulisher
Apr 22, 2025

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain (NASDAQ:CLDX) - Seeking Alpha

Apr 22, 2025
pulisher
Apr 21, 2025

Commit To Purchase Celldex Therapeutics At $15, Earn 20.1% Annualized Using Options - Nasdaq

Apr 21, 2025
pulisher
Apr 16, 2025

Urticaria Pipeline: 20+ Innovators Driving the Next Wave of Advanced Treatment Options | DelveInsight - openPR.com

Apr 16, 2025
pulisher
Apr 10, 2025

Vanguard Group Inc. Acquires 12,213 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

Apr 10, 2025
pulisher
Apr 10, 2025

Celldex stock touches 52-week low at $14.57 amid market challenges - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Celldex stock touches 52-week low at $14.57 amid market challenges By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 07, 2025

KLP Kapitalforvaltning AS Takes $306,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

Apr 07, 2025
pulisher
Apr 06, 2025

Corebridge Financial Inc. Reduces Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

Apr 06, 2025
pulisher
Apr 03, 2025

Global Cholera Vaccines Market Detailed In New Research Report - openPR.com

Apr 03, 2025
pulisher
Apr 01, 2025

Celldex Therapeutics Enters Oversold Territory (CLDX) - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Teacher Retirement System of Texas Buys 2,819 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Celldex stock touches 52-week low at $18.52 amid market challenges - Investing.com Philippines

Mar 31, 2025
pulisher
Mar 31, 2025

Celldex stock touches 52-week low at $18.52 amid market challenges By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 30, 2025

When (CLDX) Moves Investors should Listen - news.stocktradersdaily.com

Mar 30, 2025
pulisher
Mar 27, 2025

Swiss National Bank Increases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

Global Cholera Vaccines Market Business Outlook ,Growth - openPR.com

Mar 27, 2025
pulisher
Mar 23, 2025

Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews

Mar 23, 2025
pulisher
Mar 23, 2025

Why Celldex Deserves Your Attention? - RTTNews

Mar 23, 2025
pulisher
Mar 22, 2025

Charles Schwab Investment Management Inc. Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

7 Analysts Have This To Say About Celldex Therapeutics - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Celldex a new overweight at Morgan Stanley on urticaria candidate - Seeking Alpha

Mar 20, 2025
pulisher
Mar 20, 2025

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight Recommendation - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

MS starts coverage on Celldex, bullish view on company's skin disease treatment - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target -March 20, 2025 at 07:14 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 18, 2025

Personalized Cancer Vaccines Market | Growth, Innovations & - openPR

Mar 18, 2025
pulisher
Mar 16, 2025

Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $55.38 - The AM Reporter

Mar 16, 2025
pulisher
Mar 14, 2025

Strategies for Managing Chronic Spontaneous Urticaria - Medscape

Mar 14, 2025
pulisher
Mar 12, 2025

Celldex Therapeutics Inc’s Stock Price Plummeted Recently, But There Might Be Trouble Ahead - stocksregister.com

Mar 12, 2025

Celldex Therapeutics Inc (CLDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$68.28
price up icon 0.60%
$20.60
price up icon 0.88%
$32.75
price up icon 1.99%
$24.29
price up icon 0.37%
$92.80
price down icon 2.05%
biotechnology ONC
$232.25
price down icon 3.93%
大文字化:     |  ボリューム (24 時間):